CureVac berichtet positive Ergebnisse aus niedrig dosierter 1 µg Phase-1-Studie mit Tollwut-Impfstoff
January 07, 2020 07:00 ET
|
CureVac AG
Impfung induziert selbst bei niedriger Dosierung bei sämtlichen Probanden eine Immunantwort und ist gut verträglich Klinische Ergebnisse unterstreichen Potenzial von CureVacs...
CureVac Announces Positive Results in Low Dose – 1 µg – Rabies Vaccine Clinical Phase 1 Study
January 07, 2020 07:00 ET
|
CureVac AG
Low dose vaccination induced immune response in all subjects and was well tolerated Clinical results underline potency of CureVac’s technology platform Detailed results to be presented at an upcoming...
Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics
December 19, 2019 11:05 ET
|
CureVac AG
Company Announcement Genmab and CureVac enter broad strategic partnership Companies to conduct joint research on first program; option for Genmab to initiate three additional programs during 5-year...
CureVac erhält Herstellungserlaubnis für dritte GMP-Produktion
December 02, 2019 07:00 ET
|
CureVac AG
Alle drei GMP-Produktionen von CureVac können damit Wirkstoffe für präklinische und klinische Tests sowie für die frühe Markteinführung herstellen TÜBINGEN, Deutschland und BOSTON, Dec. 02,...
CureVac Granted Manufacturing Authorization for its Third GMP Production Suite
December 02, 2019 07:00 ET
|
CureVac AG
CureVac’s GMP I, II and III Combined Production Suite Scales Up Capacity to Meet All Preclinical, Clinical and Early Launch Needs for Proprietary and Partnered Programs TÜBINGEN, Germany and...
CureVac to Present at the 31st Annual Piper Jaffray Healthcare Conference
November 20, 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Germany and BOSTON, Nov. 20, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Chief...
CureVac to Present CV8102 Data at SITC Conference
October 24, 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Germany and BOSTON, Oct. 24, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that it will...
CureVac Enters into an Exclusive Collaborative Research Agreement for Discovery Research in mRNA-based Lung Therapy Candidates with Yale University
August 13, 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Germany and BOSTON, Aug. 13, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced today it has entered...
CureVac to Participate in Two Panels at the ROTH RNA Revolution Conference
July 12, 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Germany and BOSTON, July 12, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Dan...
Die Europäische Kommission beruft Ingmar Hoerr, Mitgründer und Aufsichtsratsvorsitzender von CureVac, zum Beirat des Europäischen Innovationsrats
July 01, 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Deutschland und BOSTON, July 01, 2019 (GLOBE NEWSWIRE) -- Die CureVac AG, Pionier im Bereich mRNA-basierter Impfstoffe und Therapeutika, gratuliert CureVacs Mitgründer und...